Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 275

1.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E.

Eur J Cancer. 2014 Jul 16. pii: S0959-8049(14)00759-X. doi: 10.1016/j.ejca.2014.06.015. [Epub ahead of print]

PMID:
25042151
[PubMed - as supplied by publisher]
2.

A functional interplay between ZNF217 and Estrogen Receptor alpha exists in luminal breast cancers.

Nguyen NT, Vendrell JA, Poulard C, Győrffy B, Goddard-Léon S, Bièche I, Corbo L, Le Romancer M, Bachelot T, Treilleux I, Cohen PA.

Mol Oncol. 2014 Jun 10. pii: S1574-7891(14)00120-3. doi: 10.1016/j.molonc.2014.05.013. [Epub ahead of print]

PMID:
24973012
[PubMed - as supplied by publisher]
3.

Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts.

Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E.

Clin Cancer Res. 2014 Jun 19. [Epub ahead of print]

PMID:
24947930
[PubMed - as supplied by publisher]
4.

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M.

Br J Cancer. 2014 Jul 1;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.

PMID:
24762958
[PubMed - in process]
5.

Control of MT1-MMP transport by atypical PKC during breast-cancer progression.

Rossé C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bièche I, Parker PJ, Chavrier P.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):E1872-9. doi: 10.1073/pnas.1400749111. Epub 2014 Apr 21.

PMID:
24753582
[PubMed - indexed for MEDLINE]
6.

Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.

Estrabaud E, Lapalus M, Broët P, Appourchaux K, De Muynck S, Lada O, Martinot-Peignoux M, Bièche I, Valla D, Bedossa P, Marcellin P, Vidaud M, Asselah T.

J Virol. 2014 Jun;88(11):6394-402. doi: 10.1128/JVI.00016-14. Epub 2014 Mar 26.

PMID:
24672032
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.

Bieche I, Vacher S, Vallerand D, Richon S, Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E, Roman-Roman S, Decaudin D, Dangles-Marie V.

BMC Cancer. 2014 Mar 13;14:178. doi: 10.1186/1471-2407-14-178.

PMID:
24625025
[PubMed - in process]
Free PMC Article
8.

Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.

d'Audigier C, Gautier B, Yon A, Alili JM, Guérin CL, Evrard SM, Godier A, Haviari S, Reille-Serroussi M, Huguenot F, Dizier B, Inguimbert N, Borgel D, Bièche I, Boisson-Vidal C, Roncal C, Carmeliet P, Vidal M, Gaussem P, Smadja DM.

Angiogenesis. 2014 Jul;17(3):603-16. doi: 10.1007/s10456-013-9413-2. Epub 2014 Jan 14.

PMID:
24419917
[PubMed - in process]
9.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J.

Ann Oncol. 2014 Jan;25(1):126-31. doi: 10.1093/annonc/mdt418. Epub 2013 Nov 26.

PMID:
24285021
[PubMed - in process]
10.

PIK3R1 underexpression is an independent prognostic marker in breast cancer.

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, Bièche I.

BMC Cancer. 2013 Nov 14;13:545. doi: 10.1186/1471-2407-13-545.

PMID:
24229379
[PubMed - indexed for MEDLINE]
Free Article
11.

The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.

Luscan A, Shackleford G, Masliah-Planchon J, Laurendeau I, Ortonne N, Varin J, Lallemand F, Leroy K, Dumaine V, Hivelin M, Borderie D, De Raedt T, Valeyrie-Allanore L, Larousserie F, Terris B, Lantieri L, Vidaud M, Vidaud D, Wolkenstein P, Parfait B, Bièche I, Massaad C, Pasmant E.

Clin Cancer Res. 2014 Jan 15;20(2):358-71. doi: 10.1158/1078-0432.CCR-13-0780. Epub 2013 Nov 11.

PMID:
24218515
[PubMed - in process]
12.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.

J Mol Diagn. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

PMID:
24183959
[PubMed - in process]
13.

Inhibitory signalling to the Arp2/3 complex steers cell migration.

Dang I, Gorelik R, Sousa-Blin C, Derivery E, Guérin C, Linkner J, Nemethova M, Dumortier JG, Giger FA, Chipysheva TA, Ermilova VD, Vacher S, Campanacci V, Herrada I, Planson AG, Fetics S, Henriot V, David V, Oguievetskaia K, Lakisic G, Pierre F, Steffen A, Boyreau A, Peyriéras N, Rottner K, Zinn-Justin S, Cherfils J, Bièche I, Alexandrova AY, David NB, Small JV, Faix J, Blanchoin L, Gautreau A.

Nature. 2013 Nov 14;503(7475):281-4. doi: 10.1038/nature12611. Epub 2013 Oct 16.

PMID:
24132237
[PubMed - indexed for MEDLINE]
14.

IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.

Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P, Lada O.

J Viral Hepat. 2014 Jul;21(7):525-32. doi: 10.1111/jvh.12177. Epub 2013 Oct 10.

PMID:
24118626
[PubMed - in process]
15.

α6-Integrin is required for the adhesion and vasculogenic potential of hemangioma stem cells.

Smadja DM, Guerin CL, Boscolo E, Bieche I, Mulliken JB, Bischoff J.

Stem Cells. 2014 Mar;32(3):684-93. doi: 10.1002/stem.1539.

PMID:
24022922
[PubMed - in process]
16.

Identification of PHRF1 as a tumor suppressor that promotes the TGF-β cytostatic program through selective release of TGIF-driven PML inactivation.

Ettahar A, Ferrigno O, Zhang MZ, Ohnishi M, Ferrand N, Prunier C, Levy L, Bourgeade MF, Bieche I, Romero DG, Colland F, Atfi A.

Cell Rep. 2013 Aug 15;4(3):530-41. doi: 10.1016/j.celrep.2013.07.009. Epub 2013 Aug 1.

PMID:
23911286
[PubMed - indexed for MEDLINE]
Free Article
17.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

PMID:
23875536
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis.

Masliah-Planchon J, Pasmant E, Luscan A, Laurendeau I, Ortonne N, Hivelin M, Varin J, Valeyrie-Allanore L, Dumaine V, Lantieri L, Leroy K, Parfait B, Wolkenstein P, Vidaud M, Vidaud D, Bièche I.

BMC Genomics. 2013 Jul 13;14:473. doi: 10.1186/1471-2164-14-473.

PMID:
23848554
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas.

Rème T, Hugnot JP, Bièche I, Rigau V, Burel-Vandenbos F, Prévot V, Baroncini M, Fontaine D, Chevassus H, Vacher S, Lidereau R, Duffau H, Bauchet L, Joubert D.

PLoS One. 2013 Jun 21;8(6):e66574. Print 2013.

PMID:
23805239
[PubMed - as supplied by publisher]
Free PMC Article
20.

Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.

Bieche I, Pennaneach V, Driouch K, Vacher S, Zaremba T, Susini A, Lidereau R, Hall J.

Int J Cancer. 2013 Dec 15;133(12):2791-800. doi: 10.1002/ijc.28304. Epub 2013 Aug 9.

PMID:
23736962
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk